A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Coherent Biopharma (Hefei) Co., Ltd.
Coherent Biopharma (Hefei) Co., Ltd.
Beijing Friendship Hospital
Peking University Third Hospital
European Institute of Oncology
Wellmarker Bio
SpotitEarly
University Hospital, Ghent
University of California, Davis
Lebanese University
Massachusetts General Hospital
Kineta Inc.
Shanghai Yunying Medical Technology
Fox Chase Cancer Center
Shanghai Yunying Medical Technology
Université Sorbonne Paris Nord
Manchester University NHS Foundation Trust
Chongqing Precision Biotech Co., Ltd
Peking University Cancer Hospital & Institute
The First Affiliated Hospital of Soochow University
RenJi Hospital
RenJi Hospital
Wuhan Ammunition Life-tech Co., Ltd
Provectus Pharmaceuticals
ImmVira Pharma Co. Ltd
Blue Note Therapeutics
Wellmarker Bio
Revolution Medicines, Inc.
Weprom
TScan Therapeutics, Inc.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Kyunghee University Medical Center
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
University of Maryland, Baltimore
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hyperfusion
ChineseAMS
The Clatterbridge Cancer Centre NHS Foundation Trust
SpeciCare
MetiMedi Pharmaceuticals
Institut Paoli-Calmettes
Sun Yat-sen University
Petra Pharma
University of Aarhus
The First Affiliated Hospital of Dalian Medical University
The First Affiliated Hospital of Dalian Medical University
Shenzhen BinDeBio Ltd.
Instituto do Cancer do Estado de São Paulo
M.D. Anderson Cancer Center
KU Leuven